Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting

• Published in: Oncotarget Vol. 11; no. 22; pp. 2083 - 2091
• Main Authors: Prete, Salvatore Del, Montella, Liliana, Arpino, Grazia, Buono, Giuseppe, Buonerba, Carlo, Dolce, Pasquale, Fiorentino, Olga, Aliberti, Maria, Febbraro, Antonio, Savastano, Clementina, Colantuoni, Giuseppe, Riccardi, Ferdinando, Ruggiero, Angela, Placido, Sabino De, Orditura, Michele
• Format: Journal Article
• Language: English
• Published: Impact Journals LLC 02.06.2020
• Subjects: Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.27603

Despite relevant medical advancements, metastatic breast cancer remains an uncurable disease. HER2 signaling conditions tumor behavior and treatment strategies of HER2 expressing breast cancer. Cancer treatment guidelines uniformly identify dual blockade with pertuzumab and trastuzumab plus a taxane as best first line and trastuzumab emtansine as preferred second line choice. However, there is no prospectively designed available study focusing on the sequence and outcomes of patients treated with T-DM1 following the triplet. In the following report, data concerning a wide series of patients treated in a real-life setting are presented. Results obtained in terms of response and median progression free survival suggests a significant role for T-DM1 in disease control of metastatic HER2 expressing breast cancer.